BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS. Protons vs Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019;105:64-72. [PMID: 30684667 DOI: 10.1016/j.ijrobp.2019.01.076] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma 2021;8:57-69. [PMID: 33688489 DOI: 10.2147/JHC.S282062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shampain KL, Hackett CE, Towfighi S, Aslam A, Masch WR, Harris AC, Chang SD, Khanna K, Mendiratta V, Gabr AM, Owen D, Mendiratta-Lala M. SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY) 2021;46:3615-24. [PMID: 33963419 DOI: 10.1007/s00261-021-03107-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mortensen HR, Villadsen GE, Worm ES, Weber B. Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience. Scand J Gastroenterol 2021;56:259-65. [PMID: 33430663 DOI: 10.1080/00365521.2020.1869822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
5 Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, Tanabe KK, Allen JN, Drapek LC, Qadan M, Murphy JE, Eyler CE, Ryan DP, Hong TS, Wo JY. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2020;27:1122-9. [PMID: 31873931 DOI: 10.1245/s10434-019-08142-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
7 Simone CB 2nd, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol 2020;30:253-61. [PMID: 32503791 DOI: 10.1016/j.semradonc.2020.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chandra RA, Keane FK, Voncken FEM, Thomas CR Jr. Contemporary radiotherapy: present and future. Lancet 2021;398:171-84. [PMID: 34166607 DOI: 10.1016/S0140-6736(21)00233-6] [Reference Citation Analysis]
9 Chow R, Simone CB 2nd, Jairam MP, Swaminath A, Boldt G, Lock M. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data. Acta Oncol 2022;61:484-94. [PMID: 34846988 DOI: 10.1080/0284186X.2021.2009563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Choe JW, Lee HY, Rim CH. Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis? World J Gastroenterol 2022; 28(7): 704-714 [DOI: 10.3748/wjg.v28.i7.704] [Reference Citation Analysis]
11 Wu YY, Fan KH. Proton therapy for prostate cancer: current state and future perspectives. Br J Radiol 2021;:20210670. [PMID: 34558308 DOI: 10.1259/bjr.20210670] [Reference Citation Analysis]
12 Kim KS, Wu HG. Who Will Benefit from Charged-Particle Therapy? Cancer Res Treat 2021;53:621-34. [PMID: 34176253 DOI: 10.4143/crt.2021.299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wojcieszynski AP, Ben-josef E. First Do No Harm; How to Prevent Liver Decompensation After Radiation Therapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2019;105:87-9. [DOI: 10.1016/j.ijrobp.2019.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Raldow A, Lamb J, Hong T. Proton beam therapy for tumors of the upper abdomen. Br J Radiol 2020;93:20190226. [PMID: 31430202 DOI: 10.1259/bjr.20190226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Grewal HS, Ahmad S, Jin H. Performance evaluation of adaptive aperture's static and dynamic collimation in a compact pencil beam scanning proton therapy system: A dosimetric comparison study for multiple disease sites. Med Dosim 2021;46:179-87. [PMID: 33279369 DOI: 10.1016/j.meddos.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
17 Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, Owen D, Pursley J, Schaub SK, Smith G, Venepalli NK, Zibari G, Cardenes H. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2021:S1879-8500(21)00233-2. [PMID: 34688956 DOI: 10.1016/j.prro.2021.09.004] [Reference Citation Analysis]
18 Romesser PB, Tyagi N, Crane CH. Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases. Cancers (Basel) 2021;13:1636. [PMID: 33915810 DOI: 10.3390/cancers13071636] [Reference Citation Analysis]
19 Iizumi T, Okumura T, Sekino Y, Takahashi H, Tsai YL, Takizawa D, Ishida T, Hiroshima Y, Nakamura M, Shimizu S, Saito T, Numajiri H, Mizumoto M, Nakai K, Sakurai H. Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma. J Radiat Res 2021;62:682-7. [PMID: 34036362 DOI: 10.1093/jrr/rrab040] [Reference Citation Analysis]
20 Romesser PB, Neal BP, Crane CH. External Beam Radiation Therapy for Liver Metastases. Surg Oncol Clin N Am 2021;30:159-73. [PMID: 33220803 DOI: 10.1016/j.soc.2020.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Lee G, Kim DW, Oladeru OT, Niemierko A, Gergelis KR, Haddock MG, Toesca DAS, Koong AJ, Owen D, Weekes C, Hong TS, Chang DT, Hallemeier CL, Wo JY. Liver Metastasis-Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients: Data From a Multi-institutional Retrospective Study. Pancreas 2021;50:736-43. [PMID: 34016893 DOI: 10.1097/MPA.0000000000001822] [Reference Citation Analysis]
22 Goossens ME, Van den Bulcke M, Gevaert T, Meheus L, Verellen D, Cosset JM, Storme G. Is there any benefit to particles over photon radiotherapy? Ecancermedicalscience 2019;13:982. [PMID: 32010206 DOI: 10.3332/ecancer.2019.982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Siregar H, Bäumer C, Blanck O, Chan M, Engwall E, Plaude S, Spaan B, Timmermann B, Wulff J. Mitigation of motion effects in pencil-beam scanning – Impact of repainting on 4D robustly optimized proton treatment plans for hepatocellular carcinoma. Zeitschrift für Medizinische Physik 2020. [DOI: 10.1016/j.zemedi.2020.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lin SY, Chen CM, Huang BS, Lai YC, Pan KT, Lin SM, Chu SY, Tseng JH. A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. PLoS One 2021;16:e0249003. [PMID: 33755701 DOI: 10.1371/journal.pone.0249003] [Reference Citation Analysis]
25 Cheng JY, Liu CM, Wang YM, Hsu HC, Huang EY, Huang TT, Lee CH, Hung SP, Huang BS. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. Radiat Oncol 2020;15:159. [PMID: 32605627 DOI: 10.1186/s13014-020-01605-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
26 Huang YL, Deisher AJ, Herman MG, Kruse JJ, Mahajan A. Reduce Patient Treatment wait time in a Proton Beam Facility - A Gatekeeper Approach. J Med Syst 2021;45:80. [PMID: 34258667 DOI: 10.1007/s10916-021-01756-1] [Reference Citation Analysis]
27 Jackson WC, Hartman HE, Gharzai LA, Maurino C, Karnak DM, Mendiratta-Lala M, Parikh ND, Mayo CS, Haken RKT, Schipper MJ, Cuneo KC, Lawrence TS. The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2021;111:127-34. [PMID: 33878421 DOI: 10.1016/j.ijrobp.2021.04.012] [Reference Citation Analysis]
28 Chuong M, Kaiser A, Molitoris J, Mendez Romero A, Apisarnthanarax S. Proton beam therapy for liver cancers. J Gastrointest Oncol 2020;11:157-65. [PMID: 32175119 DOI: 10.21037/jgo.2019.04.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dionisi F, Brolese A, Siniscalchi B, Giacomelli I, Fracchiolla F, Righetto R, Morganti AG, Pravadelli C, Avancini I, Rozzanigo U, Mattiuzzi A, Frisinghelli M, Pertile R, Ciarleglio FA, Vitale A, Schwarz M, Amichetti M. Clinical results of active scanning proton therapy for primary liver tumors. Tumori 2021;107:71-9. [PMID: 32648818 DOI: 10.1177/0300891620937809] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Chamseddine I, Kim Y, De B, El Naqa I, Duda DG, Wolfgang J, Pursley J, Paganetti H, Wo J, Hong T, Koay EJ, Grassberger C. Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. JCO Clin Cancer Inform 2022;6:e2100169. [PMID: 35192402 DOI: 10.1200/CCI.21.00169] [Reference Citation Analysis]
32 Bhangoo RS, Mullikin TC, Ashman JB, Cheng TW, Golafshar MA, DeWees TA, Johnson JE, Shiraishi S, Liu W, Hu Y, Merrell KW, Haddock MG, Krishnan S, Rule WG, Sio TT, Hallemeier CL. Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. Adv Radiat Oncol 2021;6:100675. [PMID: 34409199 DOI: 10.1016/j.adro.2021.100675] [Reference Citation Analysis]
33 Chhabra AM, Choi JI, Hasan S, Press RH, Simone CB 2nd. Prioritization of Proton Patients in the COVID-19 Pandemic: Recommendations from The New York Proton Center. Int J Part Ther 2020;6:38-44. [PMID: 32582818 DOI: 10.14338/IJPT-20-00022.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Uchinami Y, Katoh N, Suzuki R, Kanehira T, Tamura M, Takao S, Matsuura T, Miyamoto N, Fujita Y, Koizumi F, Taguchi H, Yasuda K, Nishioka K, Yokota I, Kobashi K, Aoyama H. A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity. Clinical and Translational Radiation Oncology 2022;35:70-5. [DOI: 10.1016/j.ctro.2022.05.004] [Reference Citation Analysis]
35 Tsang DS, Craig T, Mishra L, Dawson LA. In Regard to Sanford et al. Int J Radiat Oncol Biol Phys 2019;105:230-1. [PMID: 31422810 DOI: 10.1016/j.ijrobp.2019.03.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Sung W, Grassberger C, McNamara AL, Basler L, Ehrbar S, Tanadini-Lang S, Hong TS, Paganetti H. A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy. Radiother Oncol 2020;151:73-81. [PMID: 32679308 DOI: 10.1016/j.radonc.2020.07.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Shimizu S, Mizumoto M, Okumura T, Li Y, Baba K, Murakami M, Ishida T, Nakamura M, Hiroshima Y, Iizumi T, Saito T, Numajiri H, Nakai K, Hata M, Sakurai H. Proton beam therapy for a giant hepatic hemangioma: A case report and literature review. Clin Transl Radiat Oncol 2021;27:152-6. [PMID: 33665385 DOI: 10.1016/j.ctro.2021.01.014] [Reference Citation Analysis]
38 Tsai YL, Takei H, Iizumi T, Okumura T, Sekino Y, Numajiri H, Ishikawa H, Sakae T, Sakurai H. Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma. J Radiat Res 2021;62:133-41. [PMID: 33392617 DOI: 10.1093/jrr/rraa098] [Reference Citation Analysis]
39 Abousaida B, Seneviratne D, Hoppe BS, Ko SJ, Asaithamby A, Cucinotta FA, Kirwan JM, Mody K, Toskich B, Ashman JB, Hallemeier CL, Krishnan S. Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1169-79. [PMID: 34595139 DOI: 10.2147/JHC.S292516] [Reference Citation Analysis]
40 Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, Hwang M, Brock KK, Yeap BY, Wolfgang JA, Hong TS, Grassberger C. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. Int J Radiat Oncol Biol Phys 2020;107:986-95. [PMID: 32353390 DOI: 10.1016/j.ijrobp.2020.04.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
41 Jackson WC, Tang M, Maurino C, Mendiratta-Lala M, Parikh ND, Matuszak MM, Dow JS, Cao Y, Mayo CS, Ten Haken RK, Schipper MJ, Cuneo KC, Owen D, Lawrence TS. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease. Int J Radiat Oncol Biol Phys 2021;109:212-9. [PMID: 32853708 DOI: 10.1016/j.ijrobp.2020.08.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Sharma NK, Kappadath SC, Chuong M, Folkert M, Gibbs P, Jabbour SK, Jeyarajah DR, Kennedy A, Liu D, Meyer JE, Mikell J, Patel RS, Yang G, Mourtada F. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. Brachytherapy 2022. [DOI: 10.1016/j.brachy.2022.04.004] [Reference Citation Analysis]
43 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
44 Heller M, Parikh ND, Fidelman N, Owen D. Frontiers of therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3648-59. [PMID: 33837453 DOI: 10.1007/s00261-021-03065-0] [Reference Citation Analysis]
45 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
46 Chilukuri S, Panda PK, Jalali R. Proton Therapy in LMICs: Is the Need Justified? JCO Glob Oncol 2022;8:e2100268. [PMID: 35025690 DOI: 10.1200/GO.21.00268] [Reference Citation Analysis]
47 Lee A, Kang JJ, Bernstein H, Marqueen KE, Neal B, Kelly CM, Dickson MA, Jillian Tsai C, Tap W, Singer S, Alektiar K, Lee NY. Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Med 2021;10:4221-7. [PMID: 34085781 DOI: 10.1002/cam4.3646] [Reference Citation Analysis]
48 Cozzi L, Comito T, Loi M, Fogliata A, Franzese C, Franceschini D, Clerici E, Reggiori G, Tomatis S, Scorsetti M. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technol Cancer Res Treat 2020;19:1533033820980412. [PMID: 33287650 DOI: 10.1177/1533033820980412] [Reference Citation Analysis]
49 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Lewis S, Barry A, Hawkins M. Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.021] [Reference Citation Analysis]
51 Simone CB 2nd. First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer. J Clin Oncol 2020;38:2952-5. [PMID: 32706638 DOI: 10.1200/JCO.20.01405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Parzen JS, Hartsell W, Chang J, Apisarnthanarax S, Molitoris J, Durci M, Tsai H, Urbanic J, Ashman J, Vargas C, Stevens C, Kabolizadeh P. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group. Radiat Oncol 2020;15:255. [PMID: 33148296 DOI: 10.1186/s13014-020-01703-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]